Warfarin sodium
ApprovedSmall molecule
Boehringer IngelheimWarfarin sodium is a small molecule that works as a Vitamin K Epoxide Reductase Complex Subunit 1 Isoform 1 Inhibitor.[2] It is being used across 10 indications, with its most advanced program in Approved.[1]
Warfarin sodium is one of 255 small molecule programs targeting Stroke. It is currently in Approved.
10
Indications
19
Total Trials
2
Active Trials
254
Competitors
Pipeline
Status by Indication[3][1]
Indication
Competition
Competitive Landscape
461 competitors in Stroke
#DrugCompanyPhaseTrials
1Warfarin sodium
Boehringer IngelheimApproved
Activase
RochePreclinical
Zometa
PfizerPreclinical
Folvite
Eli LillyPreclinical
Savella
AbbViePreclinical
Proamatine
TakedaPreclinical
Botox
RRevance Therapeutics, Inc.
Preclinical
Periactin
CCidara Therapeutics Inc., a subsidiary of Merck & Co., Inc. (Rahway, New Jersey USA)
Preclinical
Zantac 150
CChattem
Preclinical
Anticoagulants
SanofiPreclinical
Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.
Timeline
Expected Milestones
Clinical
Trials by Indication[1]
Atrial Fibrillation3 trials
Tics2 trials
Oral Anticoagulation2 trials
9 more indications
Membranous Nephropathy1 trial
Rivaroxaban in Idiopathic Membranous Nephropathy
Recruiting·—·Phase 4·NCT07404436·134 enrolled
Cirrhosis1 trial
Atorvastatin1 trial
Drug Interactions1 trial
Drug1 trial
Sources
References
- [1]
- [2]
- [3]Open Targets Platform — Drug–disease associations for Warfarin sodium. EMBL-EBI & Wellcome Sanger Institute.
- [4]
Details
Drug Info
Quick Facts
- Mechanism of Action
- Vitamin K Epoxide Reductase Complex Subunit 1 Isoform 1 Inhibitor[2]
- Modality
- Small molecule[2]
- Highest Phase
- Approved[1]
- Company